

**? logon**

\*\*\* It is now 2008/06/12 19:35:57 \*\*\*  
(Dialog time 2008/06/12 18:35:57)

```
HLIGHT set on as '' ''
>>>100 is not in the range between 1 and 50, original value 30 is used.
IGORT05 is set ON as an alias for
2,9,15,16,20,35,65,77,99,148,160,233,256,275,347,348,349,474,475,476,583,6-
10,613,621,624,634,636,810,813
IGORMEDIC is set ON as an alias for
5,34,42,43,73,74,129,130,149,155,442,444,455
IGORINSUR is set ON as an alias for 169,625,637
IGORBANK is set ON as an alias for 139,267,268,625,626
IGORTNRS is set ON as an alias for 6,63,80,108,637
IGORSHOPCOUPON is set ON as an alias for 47,570,635,PAPERSMJ,PAPERSEU
IGORINVEN is set ON as an alias for 6,7,8,14,34,94,434
IGORFUNDTRANS is set ON as an alias for 608
```

? b igor705

```
>>> 7 does not exist
>>> 233 does not exist
>>> 476 does not exist
>>>3 of the specified files are not available
12jun08 17:36:11 User268082 Session D105.1
$0.00 0.238 DialUnits File415
$0.00 Estimated cost File415
$0.06 INTERNET
$0.06 Estimated cost this search
$0.06 Estimated total session cost 0.238 DialUnits
```

```

SYSTEM:OS - DIALOG OneSearch
File 2:INSPEC 1898-2008/May W2
(c) 2008 Institution of Electrical Engineers
File 9:Business & Industry(R) Jul/1994-2008/Jun 05
(c) 2008 The Gale Group
File 15:ABI/Inform(R) 1971-2008/Jun 11
(c) 2008 ProQuest Info&Learning
File 16:Gale Group PROMT(R) 1990-2008/Jun 05
(c) 2008 The Gale Group
*File 16: Because of updating irregularities, the banner
update (UD=) may vary.
File 20:Dialog Global Reporter 1997-2008/Jun 12
(c) 2008 Dialog
File 35:Dissertation Abs Online 1861-2008/Nov
(c) 2008 ProQuest Info&Learning
File 65:Inside Conferences 1993-2008/Jun 12
(c) 2008 BLDSC all rts. reserv.
File 99:Wilson Appl. Sci & Tech Abs 1983-2008/Apr
(c) 2008 The H.W. Wilson Co.
File 148:Gale Group Trade & Industry DB 1976-2008/May 26
(c)2008 The Gale Group

```

File 148: The CURRENT feature is not working in File 148.  
See HELP NEWS148.

File 160:Gale Group PROMT(R) 1972-1989  
(c) 1999 The Gale Group

File 256:TecInfoSource 82-2008/Jun  
(c) 2008 Info.Sources Inc

# Save-2008-06-12\_160422

File 275:Gale Group Computer DB(TM) 1983-2008/Jun 05  
 (c) 2008 The Gale Group  
 File 347:JAPIO Dec 1976-2007/Dec(Updated 080328)  
 (c) 2008 JPO & JAPIO  
 File 348:EUROPEAN PATENTS 1978-2007/ 200823  
 (c) 2008 European Patent Office  
 File 349:PCT FULLTEXT 1979-2008/UB=20080605 UT=20080529  
 (c) 2008 WIPO/Thomson  
 File 474:New York Times Abs 1969-2008/Jun 12  
 (c) 2008 The New York Times  
 File 475:Wall Street Journal Abs 1973-2008/Jun 11  
 (c) 2008 The New York Times  
 File 583:Gale Group Globalbase(TM) 1986-2002/Dec 13  
 (c) 2002 The Gale Group  
 \*File 583: This file is no longer updating as of 12-13-2002.  
 File 610:Business Wire 1999-2008/Jun 12  
 (c) 2008 Business Wire.  
 \*File 610: File 610 now contains data from 3/99 forward.  
 Archive data (1986-2/99) is available in File 810.  
 File 613:PR Newswire 1999-2008/Jun 12  
 (c) 2008 PR Newswire Association Inc  
 \*File 613: File 613 now contains data from 5/99 forward.  
 Archive data (1987-4/99) is available in File 813.  
 File 621:Gale Group New Prod.Annou.(R) 1985-2008/May 23  
 (c) 2008 The Gale Group  
 File 624:McGraw-Hill Publications 1985-2008/Jun 12  
 (c) 2008 McGraw-Hill Co. Inc  
 \*File 624: Homeland Security & Defense and 9 Platt energy journals added  
 Please see HELP NEWS624 for more  
 File 634:San Jose Mercury Jun 1985-2008/Jun 11  
 (c) 2008 San Jose Mercury News  
 File 636:Gale Group Newsletter DB(TM) 1987-2008/Jun 05  
 (c) 2008 The Gale Group  
 File 810:Business Wire 1986-1999/Feb 28  
 (c) 1999 Business Wire  
 File 813:PR Newswire 1987-1999/Apr 30  
 (c) 1999 PR Newswire Association Inc

Set	Items	Description
---	-----	-----

? s request??? (w) (creat??? or generat???) (w) (advertiz??? or commercial???)

Processing  
 Processing  
 Processing  
 Processing  
 Processing  
 Processing  
 Processing  
 Processing  
 Processing

Processing  
 Processing  
 Processed 10 of 26 files ...

```
Processing
Processed 20 of 26 files ...
Processing
Completed processing all files
      6552611 REQUEST???
      16270652 CREAT???
      13509114 GENERAT???
      2385 ADVERTIZ???
      13859714 COMMERCIAL???
S1      1 REQUEST??? (W) (CREAT??? OR GENERAT???) (W) (ADVERTIZ???
      OR COMMERCIAL???)
```

? s modify??? (3n) (advertiz??? or commercial???)

Processing  
Processing

```
Processing
Processed 10 of 26 files ...
Completed processing all files
      802065 MODIFY???
      2385 ADVERTIZ???
      13859714 COMMERCIAL???
S2      1788 MODIFY??? (3N) (ADVERTIZ??? OR COMMERCIAL???)
```

? provid??? (w) (sample or example) (w) (advertiz??? or commercial???)

>>>Invalid syntax at or near 'OVID???'.

? s provid??? (w) (sample or example) (w) (advertiz??? or commercial???)

Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing  
Processing

Processing  
Processing

```
Processing
Processed 10 of 26 files ...
Processing
Processing
Processing
Processed 20 of 26 files ...
Processing
Completed processing all files
40193323 PROVID???
2421079 SAMPLE
7922778 EXAMPLE
2385 ADVERTIZ???
13859714 COMMERCIAL???
S3 4 PROVID??? (W) (SAMPLE OR EXAMPLE) (W) (ADVERTIZ??? OR
COMMERCIAL???)
```

**? s modify??? (w) (advertiz??? or commercial???) (w) (prototype or sample or example or exist???)**

```
Processing
Processing
Processing
Processing
Processing
```

```
Processing
Processed 10 of 26 files ...
Processing
Processed 20 of 26 files ...
Completed processing all files
802065 MODIFY???
2385 ADVERTIZ???
13859714 COMMERCIAL???
582089 PROTOTYPE
2421079 SAMPLE
7922778 EXAMPLE
10681167 EXIST???
S4 2 MODIFY??? (W) (ADVERTIZ??? OR COMMERCIAL???) (W)
(PROTOTYPE OR SAMPLE OR EXAMPLE OR EXIST???)
```

**? S modify??? (w) (advertiz??? Or commercial?) (w) (target??? Or audience or customer? Or consumer?)**

```
Processing
Processing
Processing
Processing
Processing
Processing
Processing
```

# Processing Processing Processing

```
Processing
Processing
Processing
Processed 10 of 26 files ...
Processing
Processed 20 of 26 files ...
Completed processing all files
      802065 MODIFY???
      2385 ADVERTIZ???
14412866 COMMERCIAL?
9483236 TARGET???
1795461 AUDIENCE
16746194 CUSTOMER?
10317471 CONSUMER?
S5      0 MODIFY??? (W) (ADVERTIZ??? OR COMMERCIAL?) (W) (TARGET???
      OR AUDIENCE OR CUSTOMER? OR CONSUMER?)
```

? ds

```
Set      Items  Description
S1        1  REQUEST??? (W) (CREAT??? OR GENERAT???) (W) (ADVERTIZ??? OR
      COMMERCIAL???)
S2       1788  MODIFY??? (3N) (ADVERTIZ??? OR COMMERCIAL???)
S3        4  PROVID??? (W) (SAMPLE OR EXAMPLE) (W) (ADVERTIZ??? OR COMM-
      ERCIAL???)
S4        2  MODIFY??? (W) (ADVERTIZ??? OR COMMERCIAL???) (W) (PROTOTYPE
      OR SAMPLE OR EXAMPLE OR EXIST???)
S5        0  MODIFY??? (W) (ADVERTIZ??? OR COMMERCIAL?) (W) (TARGET??? -
      OR AUDIENCE OR CUSTOMER? OR CONSUMER?)
```

>>> Retrying request [1]

? s s1 and s2 and s4

```
      1  S1
1788   S2
      2  S4
S6     0  S1 AND S2 AND S4
```

? s s1 and s4

```
      1  S1
      2  S4
S7     0  S1 AND S4
```

? s s3 and s4

4 S3  
2 S4  
S8 0 S3 AND S4

? t s1/3,k/1

**Dialog eLink:** Order File History

1/3K/1 (Item 1 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

01066614

**METHOD AND SYSTEM FOR MEDIA**

PROCEDE ET SYSTEME POUR CONTENU MULTIMEDIA

**Patent Applicant/Inventor:**

- **RISAN Hank**  
515 Washington Street, Santa Cruz, CA 95060; US; US(Residence);  
US(Nationality);
- **FITZGERALD Edward Vincent**  
100 Peach Terrace, Santa Cruz, CA 95060; US; US(Residence);  
US(Nationality);

**Legal Representative:**

- **GALLENSON Mavis S(et al)(agent)**  
Ladas & Parry, 5670 Wilshire Boulevard, Suite 2100, Los Angeles, CA  
90036; US;

	Country	Number	Kind	Date
Patent	WO	200396340	A2	20031120

ApplicationWO2003US1487820030510

PrioritiesUS200237997920020510US200237801120020510US200221824120020813US200223529320020904US200

**Designated States:** (All protection types applied unless otherwise stated

- for applications 2004+)

[EP] AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES;

FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;

PT; RO; SE; SI; SK; TR;

[OA] BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;

ML; MR; NE; SN; TD; TG;

[AP] GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;  
UG; ZM; ZW;

[EA] AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

Publication Language: English  
Filing Language: English  
Fulltext word count: 222812

### Detailed Description:

...common for users sharing media files in an uncontrolled manner to use freely distributed or **commercially** available media player applications to experience, e.g., listen, view, and/or watch, the shared...

? ds

Set	Items	Description
S1	1	REQUEST??? (W) (CREAT??? OR GENERAT???) (W) (ADVERTIZ??? OR COMMERCIAL???)
S2	1788	MODIFY??? (3N) (ADVERTIZ??? OR COMMERCIAL???)
S3	4	PROVID??? (W) (SAMPLE OR EXAMPLE) (W) (ADVERTIZ??? OR COMMERCIAL???)
S4	2	MODIFY??? (W) (ADVERTIZ??? OR COMMERCIAL???) (W) (PROTOTYPE OR SAMPLE OR EXAMPLE OR EXIST???)
S5	0	MODIFY??? (W) (ADVERTIZ??? OR COMMERCIAL?) (W) (TARGET??? - OR AUDIENCE OR CUSTOMER? OR CONSUMER?)
S6	0	S1 AND S2 AND S4
S7	0	S1 AND S4
S8	0	S3 AND S4

? t s4/3,k/1-2

**Dialog eLink:** Order File History  
4/3K/1 (Item 1 from file: 349)  
DIALOG(R)File 349: PCT FULLTEXT  
(c) 2008 WIPO/Thomson. All rights reserved.

00822685

**NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES**  
ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

### Patent Applicant/Patent Assignee:

- **HUMAN GENOME SCIENCES INC;** 9410 Key West Avenue, Rockville, MD 20850  
US; US(Residence); US(Nationality)

(For all designated states except: US)

- **ROSEN Craig A**; 22400 Rolling Hill Lane, Laytonsville, MD 20882  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **BARASH Steven C**; 111 Watkins Pond Blvd., #301, Rockville, MD 20850  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **RUBEN Steven M**; 18528 Heritage Hills Drive, Olney, MD 20832  
US; US(Residence); US(Nationality)  
(Designated only for: US)

**Patent Applicant/Inventor:**

- **ROSEN Craig A**  
22400 Rolling Hill Lane, Laytonsville, MD 20882; US; US(Residence);  
US(Nationality); (Designated only for: US)
- **BARASH Steven C**  
111 Watkins Pond Blvd., #301, Rockville, MD 20850; US;  
US(Residence); US(Nationality); (Designated only for: US)
- **RUBEN Steven M**  
18528 Heritage Hills Drive, Olney, MD 20832; US; US(Residence);  
US(Nationality); (Designated only for: US)

**Legal Representative:**

- **HOOVER Kenley K(et al)(agent)**  
Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD  
20850; US;

	Country	Number	Kind	Date
Patent	WO	200154473	A2	20010802

ApplicationWO2001US131620010117

PrioritiesUS200017906520000131US200018062820000204US200018466420000224US200018635020000302US2000

**Designated States:** (All protection types applied unless otherwise stated  
- for applications 2004+)

[EP] AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; TR;

[OA] BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;  
MR; NE; SN; TD; TG;

[AP] GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;  
UG; ZW;

[EA] AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;



Publication Language: English  
 Filing Language: English  
 Fulltext word count: 163165

**Dialog eLink: Order File History**

4/3K/2 (Item 2 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

00761432

**METHODS, CONCEPTS AND TECHNOLOGY FOR DYNAMIC COMPARISON OF PRODUCT FEATURES AND CUSTOMER PROFILE**  
**PROCEDES, CONCEPTS ET TECHNIQUE DE COMPARAISON DYNAMIQUE DE CARACTERISTIQUES D'UN PRODUIT ET DU PROFIL DES CONSOMMATEURS**

**Patent Applicant/Patent Assignee:**

- **ACCENTURE LLP**: 100 South Wacker Drive, Chicago, IL 60606  
 US; US (Residence); US (Nationality)  
 (Designated for all)

**Legal Representative:**

- **BRUESS Steven C(agent)**  
 Merchant & Gould P.C., P.O. Box 2903, Minneapolis, MN 55402-0903;  
 US;

	Country	Number	Kind	Date
Patent	WO	200073958	A2	20001207

ApplicationWO2000US1445920000524

PrioritiesUS9932081819990527

**Designated States:** (All protection types applied unless otherwise stated  
 - for applications 2004+)

AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG;  
 BR; BY; CA; CH; CN; CR; CU; CZ; DE; DK;  
 DM; DZ; EE; ES; FI; GB; GD; GE; GH; GM;  
 HR; HU; ID; IL; IN; IS; JP; KE; KG; KP;  
 KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;  
 MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL;  
 PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ;  
 TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA;  
 ZW;

[EP] AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE;

[OA] BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;  
MR; NE; SN; TD; TG;

[AP] GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;  
UG; ZW;

[EA] AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

Publication Language: English  
Filing Language: English  
Fulltext word count: 151011

### Detailed Description:

...the project team works effectively together, numerous processes  
Of  
must be integrated. A simple **example** is provided by the required  
integration between design and construction. A more subtle one is...

? s s3 and modif????

```
      4      S3
2306443  MODIF????
S9      4      S3 AND MODIF????
```

? t s9/3,k/1-4

**Dialog eLink:** Order File History

9/3K/1 (Item 1 from file: 348)  
DIALOG(R)File 348: EUROPEAN PATENTS  
(c) 2008 European Patent Office. All rights reserved.

02018194

**Secure transaction management**  
Gesicherte Transaktionsverwaltung  
Gestion de transactions securisees

**Patent Assignee:**

- **Intertrust Technologies Corp.;** (2434323)  
955 Stewart Drive; Sunnyvale, CA 94085; (US)  
(Applicant designated States: all)

**Inventor:**

- **Ginter, Karl L.**  
10404 43rd Avenue; Beltsville, MD 20705; (US)
- **Shear, Victor H.**  
5203 Battery Lane; Bethesda, MD 20814; (US)
- **Sibert, W. Olin**  
30 Ingleside Road; Lexington, MA 02173-2522; (US)
- **Spahn, Francis J.**  
2410 Edwards Avenue; El Cerrito, CA 94530; (US)
- **Van Wie, David M.**  
51430 Willamette Street; 6 Eugene, OR 97401; (US)

**Legal Representative:**

- **Beresford, Keith Denis Lewis (28273)**  
BERESFORD & Co. 16 High Holborn; London WC1V 6BX; (GB)

	Country	Number	Kind	Date	
Patent	EP	1621960	A2	20060201	(Basic)
	EP	1621960	A3	20070110	

ApplicationEP200507612919970829

PrioritiesUS70620619960830

**Designated States:**

AT; BE; CH; DE; DK; ES; FI; FR; GB; GR;  
IE; IT; LI; LU; MC; NL; PT; SE;

**Related Parent Numbers: Patent (Application):**EP 922248 (EP 97939670)

IPC	Level	Value	Position	Status	Version	Action	Source	Office
G06F-0021/00	A	I	F	B	20060101	20060913	H	EP

Abstract Word Count: 51

NOTE: 70

NOTE: Figure number on first page: 70

Type	Pub. Date	Kind	Text
------	-----------	------	------

Publication: English

Procedural: English

Application: English

Available Text	Language	Update	Word Count
CLAIMS A	(English)	200605	249
SPEC A	(English)	200605	180527
Total Word Count (Document A) 180807			
Total Word Count (Document B) 0			
Total Word Count (All Documents) 180807			

**Specification:** ...agents for parties who have rights in electronic information, to ensure that the moving, accessing, **modifying**, or otherwise using of information can be securely controlled by rules regarding how, when, where... ..interaction activities and participants. Rather, VDE supports systems by which such applications can be created, **modified**, and/or reused. As a result, the present invention answers pressing, unsolved needs by offering that reflect traditional, non-electronic relationships. They can shape and **modify** commercial relationships to accommodate the evolving needs of, and agreements among, themselves. VDE does not require electronic content providers and users to **modify** their business practices and personal preferences to conform to a metering and control application program... ..secure hardware SPU and/or corresponding software subsystem and further allowing extensive flexibility in assembling, **modifying**, and/or replacing, such modules (e.g. load modules and/or methods) in applications run...to the extent they are allowed, can independently and securely add, delete, and/or otherwise **modify** the specification of load modules and methods, as well as add, delete or otherwise **modify** related information.

Normally the party who creates a VDE content container defines the general nature... ..of rules), perhaps through a negotiation process, accepts, and/or adds to and/or otherwise **modifies**, "in place" content control information, a VDE agreement between two or more parties related to... ..templates constitute preset configurations that can normally be reconfigurable to allow for new and/or **modified** templates that reflect adaptation into new industries as they evolve or to reflect the evolution... ..concept may be used to provide individual, overall frameworks for organizations and individuals that create, **modify**, market, distribute, consume, and/or otherwise use movies, audio recordings and live performances, magazines, telephony... ..surrounding these templates changes or evolves, template applications provided under the present invention may be **modified** to meet these changes for broad use, or for more focused activities. A given VDE...s tacit or explicit agreement.

\* provide mechanisms that allow control information to "evolve" and be **modified** according, at least in part, to independently, securely delivered further control information. Said control information... ..pathway of handling of content control information, to the extent each is authorized, can establish, **modify**, and/or contribute to, permission, auditing, payment, and reporting control information related to controlling, analyzing... ..regards to certification), at least in part secure, control information can be employed to securely **modify** content

control information when content control information has flowed from one party to another party... securely processed in a VDE secure subsystem. In an alternate embodiment, control information may be **modified** by a senior party through use of their VDE installation secure sub-system after receiving... through a sequence of control information handlers, other control information that was allowed to be **modified**, and further control information representing new control information and/or mediating data. Such a control... use in "negotiating" with "in place" content control information. This can result in new or **modified** content control information and/or it might involve the selection of certain one or more... flowing "down" through different branches in an overall pathway of handling and control and being **modified** differently as it diverges down these different pathway branches. This ability of the present invention... a) "evolve," for example, the extractor of content may add new control methods and/or **modify** control parameter data, such as VDE application compliant methods, to the extent allowed by the... of the present invention include: (a) VDE system software to in part extend and/or **modify** host operating systems such that they possesses VDE capabilities, such-as enabling secure transaction processing... fields of information or information types. Fingerprinting information may be incorporated into a property by **modifying** in a normally undetectable way color frequency and/or the brightness of certain image pixels, by slightly **modifying** certain audio signals as to frequency, by **modifying** font character formation, etc. Fingerprint information, itself, should be encrypted so as to make it... for increasing the difficulty of an unauthorized individual identifying fingerprint locations and erasing and/or **modifying** fingerprint information.

\* provide smart object agents that can carry requests, data, and/or methods, including... of property management files at each location of a VDE arrangement, to accommodate new or **modified** control information, is performed in the VDE secure subsystem and under the control of secure... commercial value chain instance.

VDE agreements support evolving ("living") electronic agreement arrangements that can be **modified** by current and/or new participants through very simple to sophisticated "negotiations" between newly proposed... information submitted by a plurality of parties. A given model may be asynchronously and progressively **modified** over time in accordance with existing senior rules and such modification may be applied to... of one or more VDE control information containing objects, that is control information may be **modified** at one or more points along a chain of control information handling, so long as... a "chain of handling and control" to its employees. The office 210 may add or **modify** "rules and controls" (consistent with the "rules and controls" it receives from publishing house 214... persist unchanged from content creator 102 to content user 112; other "rules and controls" are **modified** or deleted by distributor 106; and still other "rules and controls" are added by the... compartmentalization of the secure execution space (e.g., to prevent a less trusted task from **modifying** a more trusted task). More

details are provided below in connection with a discussion of...mode" control signal provided by microprocessor 2652. In this example, microprocessor 2652 may be slightly **modified** so it can execute two "new" instructions:

"enable 'SPU' mode" instruction, and

"disable 'SPU' mode... ..access to secure memory 532, 534 or the information it contained, or to control or **modify** the state of any other security-relevant components or functions contained within CPU/SPU 2650.... ..cryptographic authentication techniques (e.g., message authentication codes) to prevent modification or replay attacks that **modify** encrypted data stored in secure memory 532, 534. Such protection may be performed utilizing either... ..different sequential steps that are reconfigurable based on requirements

components can be added, deleted or **modified** (subject to permissioning)

full control information over pre-defined and user-defined application events

events...be based on "components" that can be securely, independently deliverable, replaceable and capable of being **modified** (e.g., under appropriately secure conditions and authorizations). Moreover, the "components" may themselves be made... ..operating system. Furthermore, "operating system" functions (such as task management, or memory allocation) may be **modified** and/or replaced by an application. A common thread in the preferred embodiment's ROS... ..information by a chain of content control information handling participant for the preparation of a **modified** control information set constitutes independent, secure delivery). For example, a content creator can produce a... ..the component assemblies. ROS 602 includes security protections that can prevent an unauthorized person from **modifying** elements, and also prevent an unauthorized person from substituting elements. One can picture an unauthorized...Services Manager ("SDSM") 744 makes calls to an underlying commercial database manager 730 to obtain, **modify**, and store records in secure database 610. In the preferred embodiment, "SDSM" 744 provides a... ..Object construction stage 1230 may use information in object configuration file 1240 to assemble or **modify** a container. This process typically involves communicating a series of events to SPE 503 to...it is enforced at least in part by hardware within MMU 540 that cannot be **modified** by any software-based process executing within SPU 500.

In the preferred embodiment, access to...

**Claims:** ...of the printer so that the decryption program cannot be viewed and/or cannot be **modified** without authorization.

3. A method according to claim 1, wherein the decryption program destroys itself...

**Dialog eLink: Order File History**

9/3K/2 (Item 1 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

01044090

**20 HUMAN SECRETED PROTEINS**

20 PROTEINES HUMAINES SECRETEES

**Patent Applicant/Patent Assignee:**

- **HUMAN GENOME SCIENCES INC;** 9410 Key West Avenue, Rockville, MD 20850  
US; US(Residence); US(Nationality)  
(For all designated states except: US)
- **BIRSE Charles E;** 13822 Saddleview Drive, North Potomac, MD 20878  
US; US(Residence); GB(Nationality)  
(Designated only for: US)
- **KOMATSOU LIS George;** 9518 Garwood Street, Silver Spring, MD 20901  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **CHOI Gil H;** 11429 Potomac Oaks Drive, Rockville, MD 20850  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **OLSEN Henrik;** 182 Kenrick Place #24, Gaithersburg, MD 20878  
US; US(Residence); DK(Nationality)  
(Designated only for: US)
- **NI Jian;** 17815 Fair Lady Way, Germantown, MD 20874  
US; US(Residence); CN(Nationality)  
(Designated only for: US)
- **BAKER Kevin P;** 14006 Indian Run Drive, Darnestown, MD 20878  
US; US(Residence); GB(Nationality)  
(Designated only for: US)

**Patent Applicant/Inventor:**

- **BIRSE Charles E**  
13822 Saddleview Drive, North Potomac, MD 20878; US; US(Residence);  
GB(Nationality); (Designated only for: US)
- **KOMATSOU LIS George**  
9518 Garwood Street, Silver Spring, MD 20901; US; US(Residence);  
US(Nationality); (Designated only for: US)
- **CHOI Gil H**  
11429 Potomac Oaks Drive, Rockville, MD 20850; US; US(Residence);  
US(Nationality); (Designated only for: US)
- **OLSEN Henrik**  
182 Kenrick Place #24, Gaithersburg, MD 20878; US; US(Residence);  
DK(Nationality); (Designated only for: US)

- **NI Jian**

17815 Fair Lady Way, Germantown, MD 20874; US; US(Residence);  
CN(Nationality); (Designated only for: US)

- **BAKER Kevin P**

14006 Indian Run Drive, Darnestown, MD 20878; US; US(Residence);  
GB(Nationality); (Designated only for: US)

### Legal Representative:

- **MARTINEAU Janet M(et al)(agent)**

Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD  
20850; US;

	Country	Number	Kind	Date
Patent	WO	200372761	A1	20030904

ApplicationWO2003US481920030220

PrioritiesUS200235855420020222

**Designated States:** (All protection types applied unless otherwise stated  
- for applications 2004+)

**[EP]** AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES;  
FI; FR; GB; GR; HU; IE; IT; LU; MC; NL;  
PT; SE; SI; SK; TR;

**[OA]** BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG;

**[AP]** GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;  
UG; ZM; ZW;

**[EA]** AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

Publication Language: English

Filing Language: English

Fulltext word count: 181398

### Detailed Description:

...be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or **modified** RNA or DNA. For example, ...or DNA or both RNA and DNA. A polynucleotide may also contain one or more **modified** bases or DNA or RNA backbones **modified** for stability or for other reasons. "**Modified**" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, ilpolynucleotide" embraces chemically, enzymatically, or metabolically **modified** forms.



56

[01431 In specific embodiments, the polynucleotides of the invention are at least 15...invention can be composed of amino acids joined to each other by peptide bonds or **modified** peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be **modified** by either natural processes, such as posttranslational processing, or by chemical modification techniques which are...the invention can be assayed for functional activity (e.g.

biological activity) using or routinely **modifying** assays known in the art, as well as assays described herein. Specifically, one of skill...a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.

[01681 A **modified** version of the computer program BLASTN (Altschul, et al., J. Mol.

Biol. 215:403-410... method by which the homology/identity disclosed in the Table was determined. The fifth column **provides** a description of the PFAM/NR hit identified by each analysis. Column six provides the... which can then be ligated

108

to an RNA oligonucleotide using T4 RNA ligase. This **modified** RNA preparation can then be used as a template for first strand cDNA synthesis using...positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be **modified** while still maintaining biological activity of the protein.

177

[02831 The second strategy uses genetic...host strain may be chosen which modulates the expression of the inserted gene sequences, or **modifies** and processes the gene product in the specific fashion desired. Expression from certain promoters can...may be non-glycosylated. In addition, polypeptides of the invention may also include an initial **modified** methionine residue, in some cases as a result of host-mediated processes. Thus, it is well...or L (levorotary).

[03491 The invention encompasses polypeptides of the present invention which are differentially **modified** during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting...methionine residue as a result of prokaryotic host cell expression. The polypeptides may also be **modified** with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow...by reference in their entirety.

[03531 As mentioned, the proteins of the invention may be **modified** by either natural processes, such as posttranslational processing, or by chemical modification techniques which are...Y. Acad. Sci. 663:48-62 (1992)).

[0354] Also provided by the invention are chemically **modified** derivatives of the polypeptides of the invention which may provide additional advantages such as increased... ..glycol/propylene glycol' copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be **modified** at random positions ...acid, cysteine and combinations thereof) of the protein.

[0359] One may specifically desire proteins chemically **modified** at the N-terminus. Using ...the N-terminally pegylated material from a population of pegylated protein molecules. Selective proteins chemically **modified** at ...herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely **modified** by the addition of cysteine or biotin to -the C-terminus or N-terminus of the... ..in the art may be applied to generate multimers containing one or more of these **modified** polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by...

**Dialog eLink:** Order File History

9/3K/3 (Item 2 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

01006987

**A NOVEL PHARMACEUTICAL COMPOUND CONTAINING ABACAVIR SULFATE AND METHODS OF MAKING AND USING SAME**

NOUVEAU COMPOSE PHARMACEUTIQUE CONTENANT DU SULFATE D'ABACAVIR ET  
PROCEDES DE FABRICATION ET D'UTILISATION ASSOCIES

**Patent Applicant/Patent Assignee:**

- **NEW RIVER PHARMACEUTICALS INC;** The Governor Tyler, 1902 Downey Street, Radford, VA 24060  
US; US(Residence); US(Nationality)  
(For all designated states except: US)
- **PICARIELLO Thomas;** 203 Murphy Street, N.E., Blacksburg, VA 24060  
US; US(Residence); US(Nationality)

**Patent Applicant/Inventor:**

- **PICARIELLO Thomas**  
203 Murphy Street, N.E., Blacksburg, VA 24060; US; US(Residence);  
US(Nationality);

**Legal Representative:**

- **SCHULMAN Robert M(et al)(agent)**

Intellectual Property Department, Hulton & Williams, 1900 K Street,  
N.W., Suite 1200, Washington, DC 20006-1109; US;

	Country	Number	Kind	Date
Patent	WO	200334980	A2	20030501

ApplicationWO2001US4308920011114

PrioritiesUS200027462220001114US200024762120001114US200024762020001114US200024759520001114US2000

**Designated States:** (All protection types applied unless otherwise stated  
- for applications 2004+)

[EP] AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; TR;

[OA] BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;  
ML; MR; NE; SN; TD; TG;

[AP] GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;  
UG; ZW;

[EA] AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

Publication Language: English

Filing Language: English

Fulltext word count: 1363212

**Detailed Description:**

...purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, **modified** amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed...

**Claims:**

...sustained release

2CW002Pthrough microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed...purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives ...purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic

aids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed... purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intennixed...purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed.... purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed... purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed... purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed... purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed... purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be inten... purportedly provide sustained release through microencapsulation of the active agent in amides of dicarboxylic acids, <B>modified</B> amino acids or thermally condensed amino acids. Slow release rendering additives can also be intermixed...

## Dialog eLink: Order File History

9/3K/4 (Item 3 from file: 349)

DIALOG(R)File 349: PCT FULLTEXT

(c) 2008 WIPO/Thomson. All rights reserved.

00823115

## NUCLEIC ACIDS, PROTEINS, AND ANTIBODIES

ACIDES NUCLEIQUES, PROTEINES ET ANTICORPS

**Patent Applicant/Patent Assignee:**

- **HUMAN GENOME SCIENCES INC;** 9410 Key West Avenue, Rockville, MD 20850  
US; US(Residence); US(Nationality)  
(For all designated states except: US)

- **ROSEN Craig A**; 22400 Rolling Hill Lane, Laytonsville, MD 20882  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **BARASH Steven C**; 111 Watkins Pond Blvd., #301, Rockville, MD 20850  
US; US(Residence); US(Nationality)  
(Designated only for: US)
- **RUBEN Steven M**; 18528 Heritage Hills Drive, Olney, MD 20832  
US; US(Residence); US(Nationality)  
(Designated only for: US)

**Patent Applicant/Inventor:**

- **ROSEN Craig A**  
22400 Rolling Hill Lane, Laytonsville, MD 20882; US; US(Residence);  
US(Nationality); (Designated only for: US)
- **BARASH Steven C**  
111 Watkins Pond Blvd., #301, Rockville, MD 20850; US;  
US(Residence); US(Nationality); (Designated only for: US)
- **RUBEN Steven M**  
18528 Heritage Hills Drive, Olney, MD 20832; US; US(Residence);  
US(Nationality); (Designated only for: US)

**Legal Representative:**

- **HOOVER Kenley K(et al)(agent)**  
Human Genome Sciences, Inc., 9410 Key West Avenue, Rockville, MD  
20850; US;

	Country	Number	Kind	Date
Patent	WO	200155447	A1	20010802

Application WO2001US133020010117

Priorities US200017906520000131US200018062820000204US200018466420000224US200018635020000302US2000

**Designated States:** (All protection types applied unless otherwise stated  
- for applications 2004+)

**[EP]** AT; BE; CH; CY; DE; DK; ES; FI; FR; GB;  
GR; IE; IT; LU; MC; NL; PT; SE; TR;

**[OA]** BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML;  
MR; NE; SN; TD; TG;

**[AP]** GH; GM; KE; LS; MW; MZ; SD; SL; SZ; TZ;  
UG; ZW;

**[EA]** AM; AZ; BY; KG; KZ; MD; RU; TJ; TM;

Publication Language: English  
 Filing Language: English  
 Fulltext word count: 172486

### Detailed Description:

...be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or **modified** RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA... ..or DNA or both RNA and DNA. A polynucleotide may also contain one or more **modified** bases or DNA or RNA backbones **modified** for stability or for other reasons. "**Modified**" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically **modified** forms.

[0301

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or **modified** peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides

13

may be **modified** by either natural processes, such as posttranslational processing, or by chemical modification techniques which are...a new polynucleotide sequence by determining its identity with a mapped UniGene cluster.

[0401 A **modified** version of the computer program BLASTN (Altschul et al., J. Mol.

Biol. 215:403-410... ..s)". Table 5 is a key to the OMIM reference identification numbers (column 1), and **provides** a description of the associated disease in Column 2.

### TABLE IB

Clone 11) SEQ ID...RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase. This **modified** RNA preparation can then be used as a template for first strand cDNA synthesis using...uter uterus pT7T3-Pac us NbHPU

L0740 Scares melanocyte melanocyte pT7T3D  
 2NbHM (Pharmacia)  
 with a

**modified**  
 polylinker

L0743 Scares breast breast pT7T3D  
 2NbHBst (Pharmacia)  
 with a

**modified**

polylinker  
L0746 Soares retina retina eye pT7F3D  
N2b5HR (Pharmacia)  
with a  
**modified**  
polylinker  
L0747 Soaresfetal-hearLN heart pT7T3D  
bHH19W (Pharmacia)  
with a  
**modified**  
polylinker  
L0748 Soares fetal liver Liver and pT7T3D  
spleen I NFLS Spleen (Pharmacia)  
with a  
**modified**  
polylinker  
L0749 Soares-fetal-liver-sp Liver and pT7T3D  
leen-INFLS-SI Spleen (Pharmacia)  
with a  
**modified**  
polylinker  
L0750 Soares-fetal luna N lun,a pT7T3D  
bHL19W (Pharmacia)  
with a  
**modified**  
polylinker  
L0752 Soares-parathyroid-t parathyroid tumor parathyroid pT7T3D  
umor NbHPA aland (Phan-aacia)  
with a  
**modified**  
polylinker  
L0754 Soares placenta placenta pT7T3D  
Nb2HP (Pharmacia)  
with a  
**modified**  
po y nker  
L0755 1 Soares-placent-cL&6 placenta pT7r3D  
75  
weeks-2NbHP8to9W (Pharmacia)  
with a  
**modified**  
polylinker  
L0756 Soares-multiple@-scler multiple sclerosis pT7T3D  
rosis-2NbHMSP lesions (Pharmacia)  
with a  
**modified**  
polylinker  
V-TYPE  
L0758 Soares-testis  
@NHT PT7T3D-Pac  
(Pharmacia)

with a  
**modified**  
polylinker  
L0759 Soares-totaljetus-@N pT7T3D-Pac  
b2HF8-9w (Pharmacia)  
with a  
**modified**  
polylinker  
L0761 NCI-CGAP-CLLJ B-cell, chronic PT7T3D-Pac  
lymphotic leukemia (Pharmacia)  
with a  
**modified**  
polylinker  
L0768 NO CGAP GC4  
pooled germ cell pT7T3D-Pac  
tumors (Pharmacia)  
with a  
**modified**  
polylinker  
L0769 NCI-MAP@-I3m25 anaplastic brain pT7T3D-Pac  
oligodendroglioma (Pharmacia)  
with a  
**modified**  
polylinker  
L0777 Soares  
@NhIMN  
S I. Pooled human mixed (see pT7T3D-Pac  
melanocyte, fetal below) (Pharmacia)  
heart, and pregnant with a  
**modified**  
polylinker  
L0805 NO CGAP@-Lu24  
carcinoid lunor pT7T3D-Pac  
(Pharmacia)  
with a  
**modified**  
polylinker  
L0809 NCI-CGAP  
Pr28 prostate pT7T3D-Pac  
(Pharmacia)  
with a  
**modified**  
polylinker  
TABLE5  
OMIM Description  
Reference  
108725 Ather' osclerosis, susceptibility to  
76  
Brachydactyly, type C  
120110...positions are not critical for protein function. Thus, positions  
tolerating amino acid substitution could be **modified** while still



maintaining biological activity of the protein.

[01121 The second strategy uses genetic engineering...host strain may be chosen, which modulates the expression of the inserted gene sequences, or **modifies** and processes the gene product in the specific fashion desired. Expression from certain promoters can... may be non-glycosylated. In addition, polypeptides of the invention may also include an initial **modified** methionine residue, in some cases as a result of host-mediated processes. Thus, it is...L. (levorotary).

116

[01761 The invention encompasses polypeptides of the present invention which are differentially **modified** during or after translation, e.g., by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting... ..methionine residue as a result of procaryotic host cell expression. The polypeptides may also be **modified** with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow... their entirety.

[01801 As mentioned, the prostate gland associated proteins of the invention may be **modified** by either natural processes, such as posttranslational processing, or by chemical modification techniques which are... ..Y. Acad. Sci. 663:48-62 (1992)).

[01811 Also provided by the invention are chemically **modified** derivatives of the polypeptides of the invention which may provide additional advantages such as increased The polypeptides may be **modified** at random positions within the molecule, or at predetermined positions within the molecule and...acid, cysteine and combinations thereof) of the protein.

[01861 One may specifically desire proteins chemically **modified** at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one... ..the N-terminally pegylated material from a population of pegylated protein molecules.

Selective proteins chemically **modified** at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity...herein incorporated by reference in its entirety). Further, polypeptides of the invention may be routinely **modified** by the addition of cysteine or biotin to the C-terminus or N-terminus of... ..in the art may be applied to generate multimers containing one or more of these **modified** polypeptides (see, e.g., U.S. Patent Number 5,478,925, which is herein incorporated...reference in their entireties.

131

[02131 The antibodies of the invention include derivatives that are **modified**, i.e., by the covalent attachment of any type of molecule to the antibody such... ..example, but not by way of limitation, the antibody derivatives include antibodies that have been **modified**, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups,

proteolytic...homologous recombination. In particular, homozygous deletion of the **JH** region prevents endogenous antibody production. The **modified** embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric...host cell strain may be chosen which modulates the expression of the inserted sequences, or **modifies** and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation...e.g., vincristine and vinblastine).

[02551 The conjugates of the invention can be used for **modifying** a given biological response, the therapeutic agent or drug moiety is not to be construed...of skill in the art would be knowledgeable as to the parameters that can be **modified** to increase the signal detected and to reduce the background noise. For further discussion regarding... ..of skill in the art would be knowledgeable as to the parameters that can be **modified** to increase the signal detected as well as other variations of ELISAs known in the...

?